Equillium Inc (EQ) USD0.0001
$0.07
(4.07%)
- Add to watchlist
- This stock can be held in a
$0.07
(4.07%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.07
(4.07%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Contact details
Important dates
General stock information
- Short code:
- EQ
- ISIN:
- US29446K1060
- Market cap:
- $58.17 million
- Shares in issue:
- 35.25 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.